title: Hypertension in Russia: Changes Observed After 4 Years of a Comprehensive Health System Improvement Program in the Yaroslavl Region.
abstract: Rates of cardiovascular mortality and morbidity in Russia have been among the highest in Europe. A comprehensive health system improvement program targeting better diagnosis and control of hypertension was undertaken in the Yaroslavl Region of Russia. This initiative was a joint program between clinicians, the Department of Health and Pharmacy of the Yaroslavl Region, and Novartis Pharma LLC. From 2011 to 2014, the blood pressure control rate improved substantially (94% relative improvement), the percentage of patients with a systolic blood pressure ≥180 mm Hg decreased (from 10% to 5%), and there was a reduction in stroke incidence rate from 4.6 to 3.7 per 1000 population. During this same period, significant changes were made to the way hypertension was diagnosed and treated across all regional government polyclinics, and the use of antihypertensive therapies increased.
authors.affiliation: Department of Cardiology of the Yaroslavl Regional Clinical Hospital of War Veterans, Yaroslavl, Russia.
authors.forename: Maria
authors.initials: M
authors.lastname: Mozheyko
authors.affiliation: Cardiology Center of the Yaroslavl Regional Clinical Hospital, Yaroslavl, Russia.
authors.forename: Sergey
authors.initials: S
authors.lastname: Eregin
authors.affiliation: Yaroslavl Region Department of Health and Pharmacy, Yaroslavl, Russia.
authors.forename: Natalia
authors.initials: N
authors.lastname: Danilenko
authors.affiliation: Head of Cardiology, National Immunobiological Company, Moscow, Russia.
authors.forename: Alexey
authors.initials: A
authors.lastname: Vigdorchik
authors.affiliation: Sunnybrook Health Sciences Centre, Toronto, ON, Canada.
authors.forename: Sheldon W
authors.initials: SW
authors.lastname: Tobe
authors.affiliation: Departments of Medicine, Physiology and Pharmacology and Community Health Sciences, O'Brien Institute for Public Health, Libin Cardiovascular Institute of Alberta, University of Calgary, Calgary, AB, Canada.
authors.forename: Norman
authors.initials: N
authors.lastname: Campbell
authors.affiliation: Covenant Health Misericordia-‎Mazankowski Heart Institute, Edmonton, AB, Canada.
authors.forename: Donna
authors.initials: D
authors.lastname: McLean
authors.affiliation: Novartis Pharma LLC, Moscow, Russia.
authors.forename: Zhanna
authors.initials: Z
authors.lastname: Baskakova
authors.affiliation: Novartis Pharma LLC, Moscow, Russia.
authors.forename: Ilnaz
authors.initials: I
authors.lastname: Klimovskaia
authors.affiliation: Novartis Pharma LLC, Moscow, Russia.
authors.forename: Krishnan
authors.initials: K
authors.lastname: Ramanathan
authors.affiliation: Clinical Development, Novartis Pharma AG, Basel, Switzerland.
authors.forename: David
authors.identifier: http://orcid.org/0000-0001-5306-9552
authors.initials: D
authors.lastname: Hughes
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000959:Antihypertensive Agents / Q000627:therapeutic use*; D001794:Blood Pressure; D001795:Blood Pressure Determination; D003430:Cross-Sectional Studies; D019468:Disease Management; D042241:Early Diagnosis; D005260:Female; D006293:Health Promotion / Q000458:organization & administration*; D006801:Humans; D006973:Hypertension / Q000150:complications / Q000175:diagnosis* / Q000188:drug therapy; D015994:Incidence; D008297:Male; D008875:Middle Aged; D012426:Russia / Q000453:epidemiology; D020521:Stroke / Q000453:epidemiology*; D016896:Treatment Outcome
chemical_list: D000959:Antihypertensive Agents